Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Molly Billstein Leber"'
Autor:
Emily Pherson, Todd W. Nesbit, Mary G Petrovskis, Molly Billstein Leber, Heidi A Pillen, Christy Ciccarello, Mandy C. Leonard, Celia A. Proctor, Jennifer G. Reddan
Publikováno v:
American Journal of Health-System Pharmacy. 78:907-918
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ed7085df405eb019ee8c277b342b7c7
https://doi.org/10.1093/ajhp/zxab080
https://doi.org/10.1093/ajhp/zxab080
Autor:
Nilesh Amin, Rebecca Pulk, Lydia Tran, Mahmoud A Ammar, LeeAnn Miller, Molly Billstein Leber, Marina Yazdi
Publikováno v:
American Journal of Health-System Pharmacy: AJHP
Disclaimer In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are post
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c4f58bf8e1fa0d281183e87f432c08e
https://doi.org/10.1093/ajhp/zxaa219
https://doi.org/10.1093/ajhp/zxaa219
Autor:
Dayna McManus, Rebecca Pulk, Jeffrey E Topal, Michael Guerra, Lydia Tran, Diana Lemieux, Ginger E. Rouse, Phu Huynh, Abdalla A. Ammar, Bryan McGill, LeeAnn Miller, Mahmoud A Ammar, Matthew W. Davis, Molly Billstein Leber, Nilesh Amin, Marina Yazdi
Publikováno v:
Journal of the American College of Clinical Pharmacy
As medication experts, clinical pharmacists play an active and dynamic role in a medication shortage response. Supplementing existing guidelines with an actionable framework of discrete activities to support effective medication shortage responses ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5deec661859858d26a74eb2e9c85c68
http://europepmc.org/articles/PMC8250559
http://europepmc.org/articles/PMC8250559
Autor:
Molly Billstein, Leber
Publikováno v:
The American journal of managed care. 24
With the passing and implementation of the Biologics Price Competition and Innovation Act in 2010, biosimilars became a new classification of FDA-approved drugs. The biosimilar classification, created with a streamlined drug approval process, was int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cfdd32433b871e6c8a13bb283d9c261d
https://pubmed.ncbi.nlm.nih.gov/30452214
https://pubmed.ncbi.nlm.nih.gov/30452214
Autor:
Angela T. Cassano, Jennifer J. Robertson, Col Jorge D. Carrillo, Molly Billstein-Leber, Kym Moline
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 75(19)
The goal of medication therapy is the achievement of defined therapeutic outcomes that improve a patient’s quality of life while minimizing patient risk.[1][1] There are inherent risks, both known and unknown, associated with the use of medications
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::421443addb0d7022297a775435e809be
https://pubmed.ncbi.nlm.nih.gov/30257844
https://pubmed.ncbi.nlm.nih.gov/30257844
Autor:
Molly Billstein, Leber
Publikováno v:
The American journal of managed care. 23(12 Spec)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6ab8c12160bb5b1023be0328f87998e3
https://pubmed.ncbi.nlm.nih.gov/29087661
https://pubmed.ncbi.nlm.nih.gov/29087661